跳至主要内容
临床试验/NCT07093775
NCT07093775尚未招募不适用

Prognostic Implication of Tumor Grade in Patients With Node-negative Breast Cancer Aged ≤ 50 Years With 21-gene Recurrence Scores of 11-25

Gangnam Severance Hospital0 个研究点目标入组 4,000 人开始时间: 2025年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
4,000
主要终点
Recurrence-free interval

研究概览

简要总结

To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with hormone receptor-positive, HER2-negative early-stage breast cancer
  • Patients treated between January 2011 and December 2023
  • Patients with available clinicopathologic data and 21-gene Oncotype DX assay results confirmed through electronic medical records

排除标准

  • Patients with breast cancer under the age of 20
  • Patients diagnosed with stage IV breast cancer
  • Patients for whom clinicopathologic data cannot be retrieved from electronic medical records

结局指标

主要结局

Recurrence-free interval

时间窗: through study completion, an average of 5 year

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sung Gwe Ahn

Professor

Gangnam Severance Hospital

相似试验